Antivirals have untapped potential in reducing SARS-CoV-2 related deaths

From the Brown and Janes labs, Public Health Sciences and Vaccine and Infectious Disease Divisions

While the percentage of vaccinated individuals against SARS-CoV-2 soars above 50% in many countries, viral variants including Delta and Omicron remind us that some variants are highly transmissible despite current vaccination rates. Vaccinations provide a first line of defense against virus-associated disease and transmission. Yet, additional tools such as antiviral drugs may prove effective in curbing highly transmissible SARS-CoV-2 variants during the current pandemic. Dr. Laura Matrajt, a staff scientist in the Vaccine and Infectious Disease Division, commented further on the use of antiviral drugs: “Antiviral treatments including molnupiravir and paxlovid have shown to be very effective against severe SARS-CoV-2 disease outcomes and are expected to become more available in the following months. This raises the possibility of using antivirals globally as manufacturers of both drugs have signed agreements with the UN Patent Pool for distribution in low- and middle-income countries.” In addition to reducing SARS-CoV-2-related deaths, antiviral treatments can reduce virus abundance in a person’s nasal passage, a key site of person-to-person virus transmission. However, it is unclear how implementing antiviral drugs to treat early SARS-CoV-2 infections will impact the death toll and virus transmission during the current SARS-CoV-2 pandemic. In a collaboration between researchers from the Fred Hutchinson Cancer Center’s Vaccine and Infectious Disease and Public Health Sciences Divisions, Drs. Laura Matrajt, Elizabeth Brown, Dobromir Dimitrov, and Holly Janes sought to understand the projected outcomes of increased use of antiviral drugs to treat SARS-CoV-2 related disease. The research team employed an agent-based mathematical model to assess antiviral use to treat SARS-CoV-2-related disease in four countries with different demographic structures and levels of vaccination coverage. These findings are available in a preprint form on medRxiv.

Antiviral drugs were employed as preventative treatments during the ongoing HIV epidemic and the 2009 H1N1 Influenza pandemic. To provide insight into how antivirals will impact SARS-CoV-2 related hospitalization risk and population-level transmission, Dr. Matrajt and her collaborators conducted mathematical modeling experiments using an agent-based schema for a specific population size and interaction network. Each person or “agent” in a population was assigned a specific “interaction network” combination of home and school or work depending on agent age and community sites that may act as places of transmission. Each agent was also given a SARS-CoV-2 infection condition: susceptible, infected asymptomatic, pre-symptomatic or symptomatic, recovered. In addition to these model parameters, certain assumptions were made. Of note, antivirals were assumed to reduce hospitalization risk by 88%. For modeling SARS-CoV-2 transmission, asymptomatic individuals were assumed to transmit virus 30% less than symptomatic individuals. Additionally, while antivirals can reduce virus abundance in the nasal passage, it is not clear how this will impact virus transmission. Thus, a range of secondary transmission rates were used to model different scenarios of antiviral-dependent reduction of transmission by 25, 50, 75, and 100%. Lastly, the researchers wished to generate models that emulated epidemic contexts like those of the Delta and Omicron SARS-CoV-2 variants, as these two scenarios may occur again. Specifically, the Delta-like wave represents a less transmissible variant that is moderately susceptible to vaccine-dependent transmission restriction and the Omicron-like wave represents a highly transmissible variant, only restricted in person-to-person spread for populations in which individuals have three doses of vaccinations.

SARS-CoV-2 related deaths and infections averted were projected under different daily antiviral treatment initiation rates for Omicron- and Delta-like waves in population demographics resembling the United States of America.
SARS-CoV-2 related deaths and infections averted were projected under different daily antiviral treatment initiation rates for Omicron- and Delta-like waves in population demographics resembling the United States of America. Image modified from article

The findings of these modeling experiments revealed that treating 6% of the daily symptomatic adult population with antivirals is predicted to reduce the deaths caused by an Omicron-like variant by >20% for countries with demographics like Kenya, Mexico, United States of America (USA), and Belgium. This is a striking effect for such a small percentage of daily antiviral treatments implemented, especially for antiviral treatments that can only reduce transmission by 25%. For the Delta-like wave model, increasing the daily percentage of individuals treated with antivirals moderately synergized with the effect of vaccinated populations to reduce projected deaths. This finding supported a modest benefit of vaccination and antiviral synergism to avert deaths for a Delta-like wave which was not observed for the Omicron-like wave, as only three-dose vaccinated individuals exhibited protection from the Omicron variant. The effect of antiviral treatment was also assessed for its impact on reducing virus transmission. While antiviral treatment provided limited reduction in transmission for the Omicron-like wave model, a synergism was observed in the Delta-like wave model for countries with higher rates of vaccinated individuals. Together, “We found that the widespread use of antiviral treatments can prevent large numbers of deaths,” stated Dr. Matrajt. However, the projected effect of antiviral treatments on transmission was limited even for vaccinated populations.

These modeling experiments of past SARS-CoV-2 variants support implementation of antivirals to reduce deaths irrespective of SARS-CoV-2 variant transmissibility. Once these SARS-CoV-2 antivirals become available, close monitoring of emerging SARS-CoV-2 variants as conducted by other Fred Hutch labs will be necessary to guide strategic use of limited drug supplies.

The spotlighted research was funded by the National Institutes of Health and the Council of State and Territorial Epidemiologists/CDC.

UW/Fred Hutch Cancer Consortium member Holly Janes contributed to this work.

Matrajt L, Brown ER, Cohen MS, Dimitrov D, Janes H. 2022. Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study. medRxiv. Online ahead of print.